Etude de phase IV, milticentrique, randomisee, ouverte, comparant les reactions et la douleur aux sites d'injection apres administrartion sous-cutaneed' interferon beta-1b (Betaferon(RM)) ou interferon beta-1a (Rebif(RM)) pendant la periode de troi mois d'initiation de la therapie chez des patients atteints d'une forme recurrente/remittente de sclerose en plaques. AVANTAGE: Analyse comparative des reactions aux sites d'injection sur venues apres administration de betaferon 25 microg ou rebif 44 microg
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Interferon beta-1b (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms AVANTAGE
- Sponsors Bayer HealthCare Pharmaceuticals
- 12 Jan 2012 Company (Bayer Healthcare) added as reported by ClinicalTrials.gov.
- 25 Sep 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Sep 2008 Actual end date changed from 1 Dec 2007 to 1 May 2008 as reported by ClinicalTrials.gov.